Novan (NOVN) Peer Comparison
$0.03
$0.01
(33.46%)
As on 26-Sep-2023 09:30EDT
Market cap
$3 Mln
Revenue (TTM)
$25 Mln
P/E Ratio
--
P/B Ratio
5.1
Div. Yield
0 %
Edit
| Novan (NOVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
3 | 15,933 | 13,215 | 11,972 | 10,883 |
Revenue ($ Mln) |
25 | 692 | 831 | 5,020 | 777 |
Net Profit ($ Mln) |
1.00 | -696.24 | 54.90 | -199.00 | -191.64 |
Net Margin (%) |
4.03 | -100.64 | 6.61 | -3.96 | -24.68 |
RoE (%) |
-- | -- | 8.11 | -3.03 | -223.36 |
Price to Earnings |
-- | -- | 271.67 | -- | -- |
Price-To-Book |
5.10 | 123.68 | 18.72 | 1.79 | 130.86 |
Income Statement ($ Mln)
| Novan (NOVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
24.71 | 77.65 | 401.86 | 4,411.00 | 50.04 |
|
Cost of Revenue
|
8.46 | 3.43 | 5.39 | 2,441.00 | 5.20 |
|
Gross Profit
|
16.23 | 74.21 | 396.47 | 1,970.00 | 44.84 |
|
Operating Expenses
|
51.89 | 586.42 | 283.84 | 1,586.00 | 224.64 |
|
Operating Profit (EBIT)
|
-35.63 | -512.20 | 112.63 | 384.00 | -179.80 |
|
Other Income
|
0.05 | 107.99 | 0.53 | -32.00 | -5.70 |
|
Profit before Tax
|
-31.99 | -484.65 | 116.19 | -72.00 | -187.13 |
|
Provision for Tax
|
-32.99 | 9.31 | 14.77 | 6.00 | 10.63 |
|
Profit after Tax (Net Income)
|
1.00 | -481.18 | 101.42 | -78.00 | -187.13 |
|
Minority Interest
|
0.00 | 11.28 | -- | -- | -- |
|
Consolidated Profit
|
-29.03 | -481.18 | 101.29 | -78.00 | -187.13 |
Liabilities ($ Mln)
| Novan (NOVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-2.83 | -1,254.62 | 501.84 | 7,289.00 | 109.56 |
|
Minority Interest
|
0.00 | 11.28 | -- | -- | -- |
|
Non-Current Liabilities
|
38.71 | 1,746.53 | 9.10 | 6,500.00 | 125.36 |
|
Current Liabilities
|
43.91 | 121.43 | 72.49 | 1,702.00 | 96.56 |
|
Total Liabilities
|
90.33 | 623.04 | 583.43 | 15,491.00 | 331.48 |
Assets ($ Mln)
| Novan (NOVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
47.11 | 74.18 | 84.18 | 12,212.00 | 85.83 |
|
Current Assets
|
32.69 | 548.85 | 499.25 | 3,279.00 | 245.64 |
|
Total Assets
|
90.33 | 623.04 | 583.43 | 15,491.00 | 331.48 |
|
Total Debt*
|
3.85 | 1,723.56 | 1.14 | 5,836.00 | 94.68 |
|
Net Current Assets
|
-11.22 | 387.45 | 426.76 | 1,577.00 | 149.08 |
Cashflow ($ Mln)
| Novan (NOVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-30.88 | -419.49 | 120.32 | 452.00 | -116.51 |
|
Cash Flow from Investing Activities
|
-- | 453.15 | -114.33 | -179.00 | -53.70 |
|
Cash from Financing Activities
|
16.02 | -13.13 | -17.28 | -549.00 | 284.58 |
|
Net Cash Inflow / Outflow
|
-- | 20.52 | 1.43 | -276.00 | -97.40 |
Ratios
Profitability Ratios
| Novan (NOVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-128.41 | -72.65 | 23.07 | -0.58 | -138.83 |
|
ROE (%)
|
-170.66 | 45.29 | 23.11 | -1.05 | -298.97 |
|
ROA (%)
|
0.71 | -58.83 | 20.14 | -0.49 | -89.27 |
|
EBIT Margin (%)
|
-144.17 | -- | -- | -- | -- |
|
Net Margin (%)
|
4.03 | -259.21 | 25.24 | -1.78 | -373.99 |
|
Cash Profit Margin (%)
|
0.00 | -- | -- | -- | -- |
Growth Ratios
| Novan (NOVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
522.99 | 0.11 | 0.10 | -0.07 | 4.67 |
|
EBIT Growth (%)
|
-0.13 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
102.91 | 14.46 | -9.86 | 83.85 | -38.68 |
|
EPS Growth (%)
|
-- | 0.17 | -0.05 | 0.84 | -0.21 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Novan (NOVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -2.37 | 23.30 | -76.53 | -17.91 |
|
Price / Book Value
|
-- | -0.91 | 4.71 | 0.82 | 30.59 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
0.25 | -6.01 | 16.71 | 13.22 | -18.50 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Novan (NOVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | -1.37 | 0.00 | 0.80 | 0.86 |
|
Short term debt to equity ratio
|
-0.16 | 0.00 | 0.00 | 0.05 | 0.00 |
|
Current Ratio
|
0.74 | 4.52 | 6.89 | 1.93 | 2.54 |
|
Quick Ratio
|
0.72 | 4.21 | 6.80 | 1.02 | 2.50 |
|
Interest Coverage
|
-19.03 | -5.03 | 31.67 | 0.72 | -24.51 |
Operating Efficiency Ratios
| Novan (NOVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
55.98 | 22.00 | 11.66 | 22.72 | 75.34 |
|
Asset Turnover
|
0.17 | 0.09 | 0.80 | 0.28 | 0.24 |
|
Receivable days
|
204.79 | 86.62 | 34.48 | 84.05 | 137.59 |
|
Inventory Days
|
90.56 | -1,646.87 | 376.03 | 217.64 | 151.78 |
|
Payable days
|
392.50 | 1,246.68 | 640.43 | 60.30 | 1,818.32 |
|
Cash Conversion Cycle
|
-97.15 | -2,806.93 | -229.91 | 241.38 | -1,528.95 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
